Finnhub•2026-04-23
Utah Medical: Q1 Earnings SnapshotUTMD — Utah Medical Products Inc
NASDAQ · Health Care · Health Care
$67.17+16.84%Market cap207.33M
- Latest Close
- $67.17
- 30-Day Move
- +16.8%
- Market Cap
- $207M
- Shares Outstanding
- 3,190,000
- P/E Ratio
- 17.23
- P/B Ratio
- 1.78
NASDAQ:UTMDHealth Care / Health CareDelayed public snapshot
Utah Medical Products Inc
A read-only Alphactor snapshot forUtah Medical Products Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$67.17
30-Day Move
+16.8%
Market Cap
$207M
Shares Outstanding
3,190,000
P/E Ratio
17.23
P/B Ratio
1.78
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$67.17
+16.8%last 90 delayed daily bars
Market cap$207M
90D High
$71.81
90D Low
$55.78
Avg Volume
14,714
What stands out
Gross margin is running at 57.1%, which gives a quick read on operating quality before you open the full model.
Net margin is 30.1%, useful for comparing UTMD against peers in Health Care.
UTMD is up 16.8% over the last 30 trading days shown on this page.
Latest operating income is $2M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$67.89
Rule of 40
31.4%
Dark Pool Short %
66.3%
Fundamentals snapshot
Latest Close
$67.17
30-Day Move
+16.8%
Market Cap
$207M
Shares Outstanding
3,190,000
P/E Ratio
17.23
P/B Ratio
1.78
ROE
11.8%
ROA
11.3%
Gross Margin
57.1%
Operating Margin
30.8%
Net Margin
30.1%
Debt / Equity
0
Current Ratio
25.64
Dividend Yield
1.9%
Latest Revenue
$9M
Financial statement snapshot
Revenue
$9M
Gross Profit
$5M
Operating Income
$2M
Net Income
$3M
Gross Margin
5710.0%
Net Margin
3008.0%
Current Ratio
25.64
Debt / Equity
0.00
Valuation snapshot
Fair Value
$67.89
Upside / Downside
+1.1%
Signal
Fairly Valued
Implied Growth
-3.0%
DCF
$59.20
EPV
$57.27
EV/Rev
$87.19
Growth Assumption
-9.7%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
$14M
Valuation spread
Current Price
$67.17
Composite Fair Value
$67.89
DCF
$59.20
EPV
$57.27
EV/Rev
$87.19
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative growth / decline priced in
Quality snapshot
Altman Z
41.02
Safe
Piotroski
5
Moderate (4-6)
Cash Conversion
1.30x
Rule of 40
31.4%
Acceptable
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $52M | $20M | $16M | $20M |
| 2023-12-31 | $50M | $17M | $17M | $22M |
| 2024-12-31 | $41M | $14M | $14M | $15M |
| 2025-12-31 | $39M | $11M | $11M | $14M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Finnhub•2026-04-23
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2026Benzinga•2026-04-23
Utah Medical Products Q1 EPS $0.82 Down From $0.92 YoY, Sales $8.722M Down From $9.710M YoYAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2025-10-31 | Koopman Brian | A | 500 | $0.00 |
| 2025-09-04 | Koopman Brian | G | 50 | $62.75 |
| 2025-08-25 | RICHINS PAUL O | G | 100 | $60.34 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| Datum One Series Trust-BRANDES SMALL CAP VALUE FUND | 144,201 | 0.05% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 101,436 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 55,408 | 0.02% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 33,429 | 0.01% | 2025-12-31 |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Micro Cap Portfolio | 32,809 | 0.01% | 2026-01-31 |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio | 31,407 | 0.01% | 2026-01-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 29,537 | 0.01% | 2026-01-31 |
| Fidelity Covington Trust-Fidelity Small-Mid Multifactor ETF | 29,436 | 0.01% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
BlackRock
Filed 2024-05-10
$15M
--
Renaissance Technologies
Filed 2025-11-13
$13M
-5.8%
Vanguard Group
Filed 2025-11-07
$11M
-0.8%
Geode Capital Management
Filed 2025-08-08
$7M
+6.5%
Dark-pool activity snapshot
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.